期刊文献+

替吉奥胶囊维持治疗晚期大肠癌疗效观察 被引量:7

原文传递
导出
摘要 目的总结替吉奥胶囊用于晚期大肠癌维持治疗的疗效和不良反应。方法选择晚期大肠癌患者32例,给予替吉奥胶囊80~120mg/d,分2次口服,连续4周休息2周为1个周期。2个周期后进行疗效评价。结果完全缓解1例,部分缓解7例,无变化10例,进展14例。总有效率为25%,临床受益率为56.3%。结论替吉奥胶囊维持治疗晚期大肠癌是一种安全有效的治疗方法,患者耐受性好,不良反应轻,值得进一步临床应用观察。
出处 《中国实用医刊》 2014年第6期123-123,共1页 Chinese Journal of Practical Medicine
  • 相关文献

参考文献5

二级参考文献20

  • 1杨新静,黄建安,雷伟,朱一蓓,张学光.共培养的树突细胞和CIK细胞对肺癌的体内外抑癌作用[J].癌症,2006,25(11):1329-1333. 被引量:30
  • 2赵文硕,张青,于洁,王笑民.加味升血汤配合化疗治疗中晚期大肠癌的临床研究[J].国际中医中药杂志,2006,28(5):306-308. 被引量:17
  • 3周际昌.实用肿瘤科学[M].2版.北京:人民卫生出版社,2003:550-559.
  • 4Ries LAG,Melbert D,Krapcho M,et al.SEER Cancer Statistics Review,1975-2004.Bethesda,MD:National Cancer Institute,Available at http://seer.cancer.gov/csr/1975_2004/.accessed November 15,2007.
  • 5Goldie JH,Coldman AJ,Gudauskas GA.Rationale for the use of alternating non-cross-resistant chemotherapy.Cancer Treat Rep,1982,66:439-449.
  • 6Petrioli R,Paolelli L,Marsili S,et al.FOLFOX-4 Stop and Go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer.Oncology,2006,70:345-350.
  • 7Sun JF,Wu RR,Norris C,et al.Safety of chronic low dose capecitabine as maintenance therapy in gastrointestinal cancers.Gastrointestinal Cancer Res,2009,3:134-140.
  • 8Li YH,Luo HY,Wang FH,et al.Phase Ⅱ study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.J Cancer Res Clin Oncol,2010,136:503-510.
  • 9Chibaudel B,Maindrault-Goebel F,Lledo G,et al.Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.J Clin Oncol,2009,27:5727-5733.
  • 10Ardavanis A,Kountourakis P,Mantzaris I,et al.Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer:a well-tolerated,active and convenient regimen.Anticancer Research,2008,28:3087-3092.

共引文献36

同被引文献60

  • 1张斌,陈虎.肿瘤免疫细胞治疗的质量管理和疗效评价[J].中国肿瘤生物治疗杂志,2015,22(1):8-15. 被引量:17
  • 2Brezden- Masley C, Polenz C. Current practices and challenges of adjuvant chemotherapy in patients with colorectal cancer [ J ]. Surg Oncol Clin N Am, 2014,23:49 -58.
  • 3van Persijn van Meerten EL, Gelderblom H, Bloem JL. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol, 2010,20:1456 -1467.
  • 4Kanazawa K, Yokouchi H, Wang X, et al. Phase 11 trial of carbopl- atin and pemetrexed as first - line chemotherapy for non - squamous non- small cell lung cancer, and correlation between the efficacy/ toxicity and genetic polymorphisms associated with pemetrexed metab- olism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902 [ J]. Cancer Chemother Pharmacol, 2014,74 : 1149 - 1157.
  • 5DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014 [ J ]. CA Cancer J Clin, 2014, 64 : 252 - 271.
  • 6Nakayama G, Kodera Y, Yokoyama H, et al. Modified FOLFOX6 with oxaliplatin stop - and - go strategy and oral S - 1 maintenance therapy in advanced colorectal cancer: CCOG -0704 study [ J ]. lnt J Clin Oncol, 2011,16:506 - 511.
  • 7Sakuramoto S, Sasako M, Yamaguchi T, et al.Adjuvant chemotherapy for gastric cancer with S-I, an oral fluoropyrimidine [J]. N Engl ~ Ned. 2007 Nov 1;357(18):1810-1820.
  • 8Miyamoto Y, Sakamoto Y, Yoshida N, et al. Efficacy of S-1 in eoloreetal eaneer [J]. Expert Opin Phannaeother,2014,15 (12): 1761-1770.
  • 9Muro K, Boku N, Shimada Y, et al. Irinotecan plus S-I(IRIS) versus fluorouraeil and folinie acid plus irinotecan (FOLFIRI) as second-line ehemotherapy for metastatic eoloreetal eaneer: a ran- domised phase 2/3 non-inferiority study (FIR1S study)[J]. Lancet Oncol, 2010,11 (9) : 853-860.
  • 10Oh SY, Ju YT, Choi SK, et al. Phase II study of irinoteean/S- 1 combination chemotherapy for patients with oxaliplatin-refraetory colorectal cancer[J]. Invest New Drugs,2011,29(5) : 1050-1056.

引证文献7

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部